Literature DB >> 21573504

miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer.

Pinar Akçakaya1, Susanne Ekelund, Iryna Kolosenko, Stefano Caramuta, Deniz M Ozata, Hong Xie, Ulrik Lindforss, Hans Olivecrona, Weng-Onn Lui.   

Abstract

Colorectal cancer (CRC) is one of the most common and deadly forms of cancer. Despite improved treatment modalities, post-operative recurrence and metastasis remain the major problems for extending patient survival after surgery. This highlights the need to search for biomarkers for prognostication and treatment stratification of colorectal cancer patients. In this study, we applied the SYBR-green quantitative PCR-based array approach to screen for differentially expressed miRNAs between patients with short (<50 months, range 10-33 months) and long survival (≥ 50 months, range 50-152 months). The selected candidate prognostic miRNAs were validated in a cohort of 50 CRC patients by TaqMan quantitative PCR. We found that high expression of miR-185 and low expression of miR-133b were correlated with poor survival (p=0.001 and 0.028, respectively) and metastasis (p=0.007 and 0.036, respectively) in colorectal cancer. Our findings suggest the potential prognostic values of these miRNAs for predicting clinical outcome after surgery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21573504     DOI: 10.3892/ijo.2011.1043

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  69 in total

Review 1.  The role of microRNAs in colorectal cancer.

Authors:  Aaron J Schetter; Hirokazu Okayama; Curtis C Harris
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

2.  MiR-185 inhibits tumor growth and enhances chemo-resistance via targeting SRY-related high mobility group box transcription factor 13 in non-small-cell carcinoma.

Authors:  Cheng Wei Zhou; Wei Jun Zhao; Yong Gang Zhu; Xiao Dong Zhao
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

Review 3.  MicroRNAs in colorectal cancer as markers and targets: Recent advances.

Authors:  Jing-Jia Ye; Jiang Cao
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

4.  Profiling of differentially expressed microRNAs (miRNAs) during differentiation of rat hepatic oval cells (HOCs) into hepatocellular carcinoma (HCC) cells.

Authors:  R H Xu; L Y Zheng; D L He; J Meng; L P Xia; X B Hao; Z Z Zhang
Journal:  Clin Transl Oncol       Date:  2014-09-26       Impact factor: 3.405

5.  miR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the E-cadherin repressor ZEB1/2.

Authors:  Peng Ma; Kan Ni; Jing Ke; Wenyi Zhang; Ying Feng; Qinsheng Mao
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-25

6.  miR-185 is an independent prognosis factor and suppresses tumor metastasis in gastric cancer.

Authors:  Zhiqin Tan; Hao Jiang; Youhua Wu; Liming Xie; Wenxiang Dai; Hailin Tang; Sanyuan Tang
Journal:  Mol Cell Biochem       Date:  2013-10-25       Impact factor: 3.396

7.  MiR-21 derived from the exosomes of MSCs regulates the death and differentiation of neurons in patients with spinal cord injury.

Authors:  Jian Kang; Zhenhuan Li; Zhongzheng Zhi; Shiqiang Wang; Guanghui Xu
Journal:  Gene Ther       Date:  2019-09-30       Impact factor: 5.250

8.  Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis.

Authors:  Lei Wang; Jeffrey Ho; Carlotta Glackin; Manuela Martins-Green
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

Review 9.  Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease.

Authors:  Keith Richard Mitchelson; Wen-Yan Qin
Journal:  World J Biol Chem       Date:  2015-08-26

Review 10.  MicroRNAs and inflammation in the pathogenesis and progression of colon cancer.

Authors:  Hirokazu Okayama; Aaron J Schetter; Curtis C Harris
Journal:  Dig Dis       Date:  2012-11-23       Impact factor: 2.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.